Bioxytran (PK) Stock Price

-0.01 (-3.03%)
Volume 51,445
Bid Price 0.28
Ask Price 0.32
News -
Day High 0.32


52 Week Range


Day Low 0.27
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Bioxytran Inc (PK) BIXT OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -3.03% 0.32 13:27:24
Open Price Low Price High Price Close Price Prev Close
0.31 0.27 0.32 0.33
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
15 51,445 $ 0.286529 $ 14,740 - 0.0002 - 0.75
Last Trade Time Type Quantity Stock Price Currency
13:03:13 500 $ 0.32 USD


Draw Mode:

Bioxytran Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 35.47M 110.84M 11.62M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
313.00 $ - - - -

more financials information »

Bioxytran (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BIXT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.45050.45050.270.361225930,648-0.1305-28.97%
1 Month0.190.580.150.427157744,0620.1368.42%
3 Months0.19990.580.150.391635722,8020.120160.08%
6 Months0.340.750.10030.399404320,137-0.02-5.88%
1 Year0.00020.750.00020.278738620,2170.3198159,900.0%
3 Years0.941.400.00010.375660820,677-0.62-65.96%
5 Years0.01591.950.00010.190018128,1010.30411,912.58%

Bioxytran (PK) Description

Bioxytran Inc., a developmental stage biotechnology company, is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule that seems to reverse hypoxia, or oxygen deficiency. During a hypothetical treatment following hypoxic brain injuries such as ischemic strokes, this molecule could be injected intravenously and then bind with oxygen molecules in the lungs in order to carry the oxygen and deliver it to the area blocked by a blood clot.

Your Recent History
Bioxytran ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.